Literature DB >> 22505475

Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time.

Elizabeth M Swisher, Toshiyasu Taniguchi, Beth Y Karlan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22505475      PMCID： PMC3341312          DOI： 10.1093/jnci/djs203

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  20 in total

1.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

Authors:  Barbara Norquist; Kaitlyn A Wurz; Christopher C Pennil; Rochelle Garcia; Jenny Gross; Wataru Sakai; Beth Y Karlan; Toshiyasu Taniguchi; Elizabeth M Swisher
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

2.  CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Authors:  Margrit M Juretzka; Richard R Barakat; Dennis S Chi; Alexia Iasonos; Jakob Dupont; Nadeem R Abu-Rustum; Elizabeth A Poynor; Carol Aghajanian; David Spriggs; Martee L Hensley; Paul Sabbatini
Journal:  Gynecol Oncol       Date:  2006-09-25       Impact factor: 5.482

3.  Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

Authors:  Andrew Berchuck; Edwin S Iversen; Johnathan M Lancaster; Jennifer Pittman; Jingqin Luo; Paula Lee; Susan Murphy; Holly K Dressman; Phillip G Febbo; Mike West; Joseph R Nevins; Jeffrey R Marks
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

4.  Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Authors:  Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

5.  Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.

Authors:  Wataru Sakai; Elizabeth M Swisher; Céline Jacquemont; Kurapaty Venkatapoorna Chandramohan; Fergus J Couch; Simon P Langdon; Kaitlyn Wurz; Jake Higgins; Emily Villegas; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

6.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Authors:  Elizabeth M Swisher; Wataru Sakai; Beth Y Karlan; Kaitlyn Wurz; Nicole Urban; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

7.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

8.  Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.

Authors:  A Gadducci; P Zola; F Landoni; T Maggino; E Sartori; T Bergamino; R Cristofani
Journal:  Gynecol Oncol       Date:  1995-07       Impact factor: 5.482

Review 9.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

10.  Resistance to therapy caused by intragenic deletion in BRCA2.

Authors:  Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962
View more
  9 in total

1.  Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

Authors:  Michael L Pearl; Huan Dong; Shaun Tulley; Qiang Zhao; Marc Golightly; Stanley Zucker; Wen-Tien Chen
Journal:  Gynecol Oncol       Date:  2015-03-11       Impact factor: 5.482

Review 2.  PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.

Authors:  Jung-Young Park; Fan Zhang; Paul R Andreassen
Journal:  Biochim Biophys Acta       Date:  2014-07-03

3.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

Authors:  Markus Riester; Wei Wei; Levi Waldron; Aedin C Culhane; Lorenzo Trippa; Esther Oliva; Sung-Hoon Kim; Franziska Michor; Curtis Huttenhower; Giovanni Parmigiani; Michael J Birrer
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

4.  Modeling Between-Study Heterogeneity for Improved Replicability in Gene Signature Selection and Clinical Prediction.

Authors:  Naim U Rashid; Quefeng Li; Jen Jen Yeh; Joseph G Ibrahim
Journal:  J Am Stat Assoc       Date:  2019-10-29       Impact factor: 5.033

5.  Identification of key gene signatures for the overall survival of ovarian cancer.

Authors:  Akash Pawar; Oindrila Roy Chowdhury; Ruby Chauhan; Sanjay Talole; Atanu Bhattacharjee
Journal:  J Ovarian Res       Date:  2022-01-20       Impact factor: 4.234

Review 6.  Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer.

Authors:  Levi Waldron; Benjamin Haibe-Kains; Aedín C Culhane; Markus Riester; Jie Ding; Xin Victoria Wang; Mahnaz Ahmadifar; Svitlana Tyekucheva; Christoph Bernau; Thomas Risch; Benjamin Frederick Ganzfried; Curtis Huttenhower; Michael Birrer; Giovanni Parmigiani
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 11.816

7.  Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells.

Authors:  Ting Liu; Le Zhao; Yan Zhang; Wei Chen; Dan Liu; Huilian Hou; Lu Ding; Xu Li
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

8.  Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.

Authors:  Michael T Zimmermann; Guoqian Jiang; Chen Wang
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2016-07-20

9.  Double-negative feedback interaction between DNA methyltransferase 3A and microRNA-145 in the Warburg effect of ovarian cancer cells.

Authors:  Songlin Zhang; Meili Pei; Zhen Li; Han Li; Yanli Liu; Jie Li
Journal:  Cancer Sci       Date:  2018-08-12       Impact factor: 6.716
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.